Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 4Breast 4Gastrointestinal 3Head & Neck 2Thoracic 1Sarcoma 1Other solid neoplasm 1Dermatologic 1

Conditions

Tobacco Use Disorder 1Precancerous Conditions 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 463Cisplatin 379Paclitaxel 313Pemetrexed 300Docetaxel 242Erlotinib Hydrochloride 240Gemcitabine 232pembrolizumab 173Radiotherapy 172Bevacizumab 169Nivolumab 130Etoposide 106Gefitinib 95Vinorelbine 84durvalumab 71atezolizumab 68Cetuximab 65Topotecan 61Drug Therapy 57Ipilimumab 55Irinotecan 54osimertinib 53Radiosurgery 52Afatinib 51Surveys and Questionnaires 38130-nm albumin-bound paclitaxel 38Albumin-Bound Paclitaxel 37Taxes 35Cyclophosphamide 35Surgical Procedures, Operative 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Sulindac × Thoracic × Clear all
NCT00368927 2014-05-23

Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

National Cancer Institute (NCI)

Phase 2 Completed
61 enrolled 11 charts
Other neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Precancerous Conditions, Tobacco Use Disorder

Data powered by HemOnc (CC BY 4.0) Colophon âš¡